Abstract:Raltegravir (RAL) is a first clinically approved integrase (IN) inhibitor for the treatment of HIV but rapid mutation of the virus has led to chemo-resistant strains. Therefore, there is a medical need to develop new IN inhibitors to overcome drug resistance. At present, several IN inhibitors are in different phases of clinical trials and few have been discontinued due to toxicity and lack of efficacy. The development of potent second-generation IN inhibitors with improved safety profiles is key for selecting new clinical candidates. In this article, we report the design and synthesis of potent 5-hydroxy-6-oxo-1,6-dihydropyrimidine-4-carboxamide analogues as second-generation IN inhibitors. These compounds satisfy two structural requirements known for potent inhibition of HIV-1 IN catalysis: a metal chelating moiety and a hydrophobic functionality necessary for selectivity against the strand transfer reaction. Most of the new compounds described herein are potent and selective for the strand transfer reaction and show antiviral activity in cell-based assays. Furthermore, this class of compounds are drug-like and suitable for further optimization and preclinical studies.

Design, Practical Synthesis, and Biological Evaluation of Novel 6-(Pyrazolylmethyl)-4-quinoline-3-carboxylic Acid Derivatives As HIV-1 Integrase Inhibitors

Design, Synthesis and Anti-HIV Integrase Evaluation of 4-Oxo-4h-quinolizine-3-carboxylic Acid Derivatives

Synthesis of 6-Sulfamoyl-4-oxoquinoline-3-carboxylic Acid Derivatives As Integrase Antagonists with Anti-Hiv Activity

Design, synthesis and antiviral activity of novel quinazolinones.

Design, synthesis and biological activity of aromatic diketone derivatives as HIV-1 integrase inhibitors.

Synthesis and Biological Activities of Quinoline Derivatives As Hiv-1 Integrase Inhibitors

Design, Synthesis and Anti-Hiv Integrase Evaluation of N-(5-chloro-8-hydroxy-2-styrylquinolin-7-yl)benzenesulfonamide Derivatives.

Design, Synthesis and Biological Evaluation of Indole-2-carboxylic Acid Derivatives As Novel HIV-1 Integrase Strand Transfer Inhibitors

Design And Synthesis Of 2-Styrylquinoline-7-Sulfonamide Derivatives As Potential Hiv Integrase Inhibitors

Design,synthesis and Biological Evaluation of Pyrrolo-Pyridine Derivatives As HIV-1 Integrase Inhibitors

Design and Synthesis of N-methylpyrimidone Derivatives As HIV-1 Integrase Inhibitors

Design and synthesis of novel N-hydroxy-dihydronaphthyridinones as potent and orally bioavailable HIV-1 integrase inhibitors.

Synthesis and Anti-HIV-1 Activity Evaluation for Novel 3a,6a-Dihydro-1H-pyrrolo[3,4-c]pyrazole-4,6-dione Derivatives.

Design and Synthesis of 5-Chloro-2-hydroxy-3-triazolylbenzoic Acids As HIV Integrase Inhibitors

Design, Synthesis and Biological Evaluation of 3-Hydroxyquinazoline-2,4(1h,3h)-diones As Dual Inhibitors of HIV-1 Reverse Transcriptase-Associated RNase H and Integrase.

Synthesis and Biological Evaluation of Novel Quinoxalinone-Based HIV-1 Reverse Transcriptase Inhibitors

Design and Discovery of 5-Hydroxy-6-oxo-1,6-dihydropyrimidine-4-carboxamide Inhibitors of HIV-1 Integrase

1-Hydroxypyrido[2,3-d]pyrimidin-2(1h)-ones As Novel Selective HIV Integrase Inhibitors Obtained Via Privileged Substructure-Based Compound Libraries

Design and synthesis of novel pyrimidone analogues as HIV-1 integrase inhibitors.

Design and Synthesis of N-hydroxytriazole-4-carboxamides As HIV Integrase Inhibitors

Design,synthesis and activity evaluation of new anti-HIV-1 CXCR4 inhibitors